Lung Cancer
Conference Coverage
More than 64% of younger adults with lung cancer diagnosed at later stages
Patients younger than 55 are diagnosed with more advanced disease and have worse survival.
Conference Coverage
Air pollution contribution to lung cancer may be underestimated
A study of women with lung cancer who never smoked suggests that air pollution may be a larger risk factor for lung cancer than currently...
Conference Coverage
Smoking cessation with lung screening ups quit rates
Offering smoking cessation support at the time and place of lung cancer screening resulted in high smoking abstinence rates at 1 year.
From the Journals
CV admissions on the rise in Americans with cancer
“I would say that this increase in cardiovascular admissions, that’s a failure from a preventative perspective.”
From the Journals
One in four NSCLC patients respond poorly to COVID-19 vaccine
The reasons are unclear, but point to the need for NSCLC patients to have titers checked.
From the Journals
Lung cancer treatment combo may be effective after ICI failure
Phase 2 trial offers hope of a chemotherapy-free option for patients with advanced NSCLC.
Conference Coverage
The shifting sands of lung cancer screening
Studies find encouraging trends of stage shifting and minority screening, but more work remains.
From the Journals
New KRAS inhibitor shows promise in NSCLC
One out of three lung cancer patients previously treated with chemotherapy and immune therapy responded to a new targeted therapy.
Opinion
Drugging the undruggable
Targeted therapies are the ideal in drug development. New drugs that target KRAS (G12C) mutations mark a significant leap forward in oncology.
Opinion
Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
Phase 3 trials are needed to determine whether neoadjuvant chemo/immunotherapy outperforms adjuvant chemo/immunotherapy.